Study | Year | Sample size | Country | Tumor type | Median follow-up (range) (month) | Therapy | Stage | NOS | Cut-off | PD-L1+Number | Antibody | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Company | Source | Type | Clone | |||||||||||
Kiyasu | 2015 | 1253 | Japan | DLBCL | NA | C + T + R | I-IV | 7 | 30% | 461 | abcam, UK | mouse | MAB | ab52587 |
2016 | 86 | USA | DLBCL | 21 (0.07–175) | C | I-IV | 6 | 30% | 14 | Cell Signaling,USA | rabbit | MAB | E1L3N | |
Dong | 2016 | 100 | China | DLBCL | 52.4 (1.5–89.1) | C | I-IV | 7 | 5% | 54 | abcam, UK | rabbit | PAB | ab153991 |
Bi | 2016 | 77 | China | NK/T | 38.0 (9.4–79.0) | C | I-II | 8 | 38% | 26 | abcam, UK | rabbit | PAB | NA |
Kim | 2016 | 73 | Korea | NK/T | 20.6 (0.2–83.2) | C + S | I-IV | 7 | 10% | 41 | Cell Signaling,USA | rabbit | MAB | E1L3N |
Fang | 2017 | 74 | China | DLBCL | 2.4–86.4 | C + S | I-IV | 8 | 10% | 20 | ZSGB-BIO | rabbit | MAB | SP142 |
Kwon | 2015 | 126 | Korea | DLBCL | 52 (16–165) | C | I-IV | 8 | 10% | 77 | Cell Signaling,USA | rabbit | MAB | E1L3N |
Blaker | 2016 | 38 | Norway | FL | 120 (15.6–408) | C + T | NA | 6 | 2% | 15 | Spring Bioscience, Pleasanton,CA,USA | rabbit | MAB | SP142 |
Jo | 2016 | 79 | Korea | NK/T | 52.4 | C + R | I-IV | 7 | 5% | 63 | R&D Systems,USA | mouse | MAB | NA |
Hu | 2017 | 204 | China | DLBCL | 52 (1–114) | C | I-IV | 8 | 5% | 100 | Cell Signaling, USA | rabbit | MAB | NA |
Cho | 2017 | 76 | Korea | PCNSL | 20.2 (2.2–128.5) | C + T | NA | 6 | ≥100 cells/HPF | 10 | Abcam, UK | rabbit | PAB | ab58810 |
Miyoshi | 2016 | 135 | Japan | ATLL | 10.9 (0.03–114.8) | C + T + R | I-IV | 8 | 50% | 10 | Abcam, UK | rabbit | MAB | ab174838 |